Clinical Trials Logo

Clinical Trial Summary

This is an early phase (phase IIa), randomized, multi-center study in subjects with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). The purpose of this study is to investigate the safety of GSK2586881 and to determine what effects it has on people with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).

The study has two parts: Part A will be an open-label investigation in five subjects. Part B will be a double-blind, placebo controlled investigation and will involve approximately 60 subjects.


Clinical Trial Description

The acute respiratory distress syndrome (ARDS) is a form of severe acute lung injury (ALI) characterized by hypoxemic respiratory failure (the lungs are unable to absorb oxygen to the arterial blood) and non-cardiogenic pulmonary edema (accumulation of fluid in the lungs). The syndrome may be caused by direct or indirect injury to the lungs. It is associated with a mortality rate of up to 40-50%. There are no marketed pharmacologic therapies for this devastating syndrome.

This study aims to assess the safety, tolerability and pharmacodynamics of GSK2586881, a recombinant human angiotensin converting enzyme type 2 (rhACE2).

ACE2 is involved in the Renin-Angiotensin System (RAS), which controls blood pressure, electrolytes and intravascular fluid volume. A key function of rhACE2 is believed to be the cleavage of Angiotensin II (Ang II) to Ang (1-7), which have opposing physiological roles. Elevated levels of Ang II are associated with vasoconstriction, inflammation, fibrosis, vascular leak, and sodium absorption. Ang (1-7) appears to be a counterregulatory protein in the RAS; associated with vasodilation, anti-proliferation, antiinflammation, and reduced vascular leak. It has been observed that levels of Ang II are increased in humans with ALI/ ARDS. It is expected that the reduction of Ang II should have a positive impact on ALI and ARDS. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01597635
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date September 1, 2012
Completion date October 6, 2014

See also
  Status Clinical Trial Phase
Completed NCT00498251 - Prevention of Lung Edema After Thoracic Surgery N/A
Completed NCT00141726 - Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Phase 2
Completed NCT00996840 - SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS Phase 2
Completed NCT03651817 - Lung Protection Strategy in Open Heart Surgery: Which Tidal Volume is Better 8ml/kg or 6ml/kg N/A
Recruiting NCT05680831 - Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air Phase 1
Completed NCT03764319 - Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO N/A
Completed NCT01640990 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers Phase 1
Completed NCT01114009 - Effects of Recruitment Maneuvers in Early Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) Patients N/A
Terminated NCT00715338 - Effects of Oxygen on Lung Tissue During Anesthesia N/A
Recruiting NCT03202641 - Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients N/A
Completed NCT03828630 - Lung Ultrasound to Detect Pulmonary Complications in Critically Ill Parturients
Completed NCT03905837 - Impact of Lidocaine Administration on Postoperative Complications During Lung Resection Surgery Phase 4
Completed NCT03023670 - Lung Protection and Pediatric Cardiac Surgery N/A
Recruiting NCT05647967 - Features of Regional Perfusion of Lung Consolidation
Recruiting NCT04289324 - Open Lung Maneuvers During High Frequency Oscillatory Ventilation in Preterm Infants N/A
Completed NCT05647382 - Soluble VE-cadherin in Prediction and Diagnosis of Early Postoperative Hypoxemia After Cardiopulmonary Bypass N/A
Completed NCT05610475 - Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass N/A
Recruiting NCT04511923 - Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury Phase 1/Phase 2
Active, not recruiting NCT03637530 - a Study Conducted About a New Mode of Ventilation in Laparoscopic Surgeries N/A
Completed NCT04344184 - SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) Phase 2